Objectives: To evaluate the effect of rapamycin pretreatment before allogenic
corneal transplant on CD4+CD25+Foxp3+T regulatory cells (Treg) in recipient
mice, and analyze its correlation with graft survival.
Materials and Methods: Balb/c mice were intraperitoneally injected with
rapamycin or control solution for 2 weeks. They then underwent a corneal
transplant with C57/BL6 serving as the donor. Graft status was assessed twice a
week. Recipient mice were killed 14 days after surgery, and the percentage of
CD4+CD25+Foxp3+Treg in peripheral blood, spleen, and draining lymph nodes was
analyzed by flow cytometry. Moreover, CD4+CD25+T cells in corneal grafts and
conjunctiva were identified, and expression of Foxp3 mRNA in the grafts was
tested. Additionally, the concentration of IL-10 and TGF-β1 in serum and
aqueous humor was measured.
Results: Pretreatment of rapamycin significantly enhanced the percentage of
CD4+CD25+Foxp3+Treg in peripheral blood and draining lymph nodes, preoperatively
and postoperatively, which had significant negative correlation with graft
opacity and neovascularization. Moreover, rapamycin pretreatment led to a larger
number of CD4+CD25+T cells infiltrating in corneal grafts and conjunctiva,
increased expression of Foxp3 mRNA in grafts, and elevated concentration of
TGF-β1 in aqueous humor.
Conclusions: Pretreatment with rapamycin for 14 days before an allogenic corneal
transplant enhances the percentage of CD4+CD25+Foxp3+Treg cells in peripheral
blood, draining lymph nodes, and grafts, thereby inhibiting graft rejection.
Key words: Rapamycin, Regulatory T cells, Corneal transplant
Corneal disease, one of the leading causes of blindness in China,1 requires a
corneal transplant to restore visual function in most cases.2 Although immune
privilege of corneal allografts endows a high success rate of corneal transplant
than other solid-organ transplants, immunologic rejection remains a major cause
of graft failure after corneal transplant.3, 4
Regulatory CD4+CD25+Foxp3+T cells (Treg), an important regulator in maintaining
immune homeostasis, play a crucial role in autoimmune diseases and tumors, and
protect individuals from graft rejection.5 However, Treg cells are present in
low numbers under normal conditions, reported to be 5% to 10% of CD4+T cells in
mice and human blood, and have an anergic phenotype.6 Therefore, enhancement of
activated Treg cells may protect individuals from autoimmune diseases and graft
rejection, just as previous studies have revealed.7-10
Rapamycin, a novel macrolide immunosuppressive drug, has been reported to
prevent clinical allograft rejections including corneal allografts.11 Moreover, rapamycin allows expansion of CD4+CD25+Foxp3+ Treg in vitro and in vivo,12-14
and CD4+CD25+Foxp3+ Treg converted by rapamycin has more-potent regulatory
abilities.15 It has been shown that adoptive transfer of CD4+CD25+Foxp3+ Treg
expanded by rapamycin in vitro is capable of promoting tolerance to allogenic
grafts.16 However, the ability of enhanced CD4+CD25+Foxp3+ Tregs, induced by in
vivo rapamycin administration before allotransplant, to prohibit rejection and
promote graft acceptance, remains unclear. Hence, we sought to explore whether
in vivo enhancement of CD4+CD25+Foxp3+ Treg, induced by rapamycin pretreatment
before allogenic corneal transplant, could protect the corneal graft in
recipient mice after surgery.
Materials and Methods
Forty Balb/c (H-2d) and 20 C57/BL6 (H-2b) female mice (weighing 20-24 g, 6-8 wk
old) were purchased from the Department of Laboratory Animal, Fudan University.
All mice were housed in a specific pathogen-free environment. All experimental
manipulations were undertaken in accordance with the Institutional Guidelines
for the Care and Use of Laboratory Animals and ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research.
Rapamycin in powder form (Wyeth Ayerst-Research, Princeton, NJ, USA [now part of
Pfizer]) was dissolved in the vehicle containing sodium CMC (C-5013 high
viscosity; Sigma-Aldrich Corp. St. Louis, MO, USA) and polysorbate 80 (P-8074,
Sigma-Aldrich). Rapamycin solution was stored at 4°C in the dark according to
the manufacturer’s instruction. The control solution only included 0.2% CMC and
0.25% polysorbate 80.
Before undergoing a corneal transplant, Balb/c mice were randomly divided into 2
groups, with each group containing 20 recipient mice. They then were
intraperitoneally injected with either rapamycin
1.5 mg/kg/d or the same volume of a control solution. The injection was
performed once per day and lasted for 2 weeks. Then 5 mice in each group were
killed, and peripheral blood, spleen, and draining lymph nodes were collected
for flow cytometric analysis. The rest of the mice underwent an allogenic
Corneal transplant (penetrating keratoplasty)
Allogenic penetrating keratoplasty was performed as previously reported.17 In
brief, C57/BL6 mice were killed by cervical dislocation, and a 2-mm diameter
trephine was used to obtain the cornea as the donor. Rapamycin or control
solution pretreated Balb/c mice, with the right eyes serving as the recipients,
were anesthetized with 100 mg/kg ketamine hydrochloride and 5 mg/kg diazepam.
After dilating the pupil by administering 0.25% tropicamide eye drops, a
1.5-mm–diameter trephine was used to cut the recipient cornea at the depth of
80% to 90%, and then paracentesis was carefully done with a 1-mL needle to avoid
damaging the lens. Viscoelastic material containing 3% sodium hyaluronate
(Healon; Advanced Medical Optics, Santa Ana, CA, USA) was injected immediately
to maintain the anterior chamber. Then, the recipient cornea was cut with a
scissors, and the donor cornea was fixed to the recipient’s bed with 8
interrupted 11-0 nylon sutures. Erythromycin eye ointment was administered in
the conjunctival sac after surgery, and the eyelids were sutured with 8-0
mattress sutures. The eyelid sutures were removed 3 days after surgery; neither
systematic nor topical immunosuppressive drugs were applied.
Assessment of the grafts
Three, 7, 10, and 14 days after surgery, all recipient mice were examined under
a slit lamp biomicroscope, and digital photographs of the cornea were taken
using a Canon 8-megapixel digital camera attached to the slit lamp
biomicroscope. Transparency of the graft and degree of neovascularization in the
graft and host tissue were recorded and scored to assess graft rejection
according to the criteria listed in Table 1, which was put forward by previous
researchers.17-18 Mice with infection, hyphema, and cataracts were excluded, and
the same quantity of recipient mice were recruited.
Flow cytometric analysis
Fifteen days after surgery, peripheral blood from the recipient mice was
collected in heparinized tubes, and the spleen and draining lymph nodes were
obtained after the animals were killed. Single cell suspension of the spleen and
lymph nodes were prepared through compression with the plunger of a 3-mL
syringe. Subsequently, cells were centrifuged and resuspended in appropriate
volume of flow cytometry staining buffer to adjust the final cell concentration
2 × 107/mL. Then, cells were stained with a mouse Treg staining kit
(eBioscience, Inc., 88-8111, San Diego, CA, USA) according to the manufacturer’s
instructions, and 3-color flow cytometry was performed. Briefly, either the
peripheral blood or cell suspension was incubated with anti-mouse CD4-FITC
(RM4-5) and anti-mouse CD25-APC (PC61.5) at 4°C for at least 30 minutes in the
dark. The cells then were rinsed with precooling flow cytometry staining buffer,
followed by treatment with 1 mL of fixation/permeabilization working solution
for 30 minutes in the dark. After washing the cells twice with the
permeabilization buffer, the cells were resuspended in 500 µL of
permeabilization buffer, and anti-mouse Foxp3-PE (FJK-16s) was added. Cells were
then incubated at 4°C for another 30 minutes in the dark, followed by 2 more
rinses with the permeabilization buffer. Finally, cells were resuspended with
the flow cytometry staining buffer, and analyzed using a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA, USA) and CellQuest software.
After killing recipient mice, the eyeballs were enucleated and fixed in the
mixture of 40% formaldehyde, 40% glacial acetic acid, and 95% ethanol for 24
hours, then dehydrated in graded ethanol solutions and embedded in paraffin wax.
The embedded tissue was cut to 4- to 6-µm–thick sections. To perform
immunofluorescence staining, the sections were firstly deparaffinized in xylene
using 3 changes for 5 minutes each, and then hydrated gradually through graded
alcohols: washed in 100% ethanol twice for 10 minutes each, then 95% ethanol
twice for 10 minutes each. Antigen retrieval was performed by heating the slides
in 10 mM sodium citrate buffer, pH 6.0, at 95ºC for 5 minutes, and then cooling
them in the buffer for approximately 20 minutes until room temperature. After
this, slices were washed with phosphate buffered saline 3 times, and excess
liquid was aspirated. After several blocking steps, the sections were incubated
with 1:100 goat anti-mouse CD4 (Santa-Cruz C-18, Santa Cruz, CA, USA) and rat
anti-mouse CD25 (PC61.5, eBioscience) for 1 hour at 37°C and then overnight at
4°C. Slices then were washed with phosphate buffered saline 3 times for 5
minutes each and incubated with Alexa Fluor 594 rabbit anti-goat IgG (HH-A11080,
Invitrogen Corporation, Carlsbad, CA, USA) and Alexa Fluor 488 rabbit anti-rat
IgG (HH-A21210, Invitrogen) for 2 hours. Finally, sections were mounted with
glycerol and examined under laser scanning confocal microscopy (TCS SP2, Leica,
Real-time polymerase chain reaction of Foxp3 in the graft
After killing recipient mice and enucleating the eyeballs, each cornea was
dissected from the limbus, and expression of the Foxp3 gene in the corneal
tissue was analyzed using quantitative real-time polymerase chain reaction.
Total RNA was extracted from homogenized dissected corneal grafts using the
Qiagen RNeasy miniKit (Qiagen, Tokyo, Japan), according to the manufacturer’s
instructions. Reverse transcription to cDNA was performed using TaqMan reverse
transcription reagents (Applied Biosystems, Foster City, CA, USA). The sequence
of forward and reverse primer was 5' CTATGCCACCCTTATCCGA 3' and 5'
TCCTCTTCTTGCGAAACTCA 3'. Mouse
β-actin was used as an endogenous control. Relative quantification assays
for Foxp3 gene expression
were performed using a StepOnePlus real-time polymerase chain reaction system
(Applied Biosystems). For each example, the threshold cycle (CT) value of Foxp3
was normalized using the formula ΔCT=CTFoxp3-CTβ-actin. The mean ΔCT was determined, and the relative foxp3 mRNA expression was calculated
Enzyme-linked immunosorbent assay
Peripheral blood and aqueous humor were collected before killing recipient mice,
and enzyme-linked immunosorbent assay was performed to test expression of
TGF-β1 and IL-10 in the serum and aqueous humor, using enzyme-linked
immunosorbent assay kits (81-BMS614/2 and
81-BMS608/3; eBioscience San Diego, CA, USA).
Data are presented as means ± SD. The t test and Kruskal-Wallis test were used
to analyze the data. The Pearson correlation analysis was performed to
explore the relation between the level of CD4+CD25+Foxp3+Tregs and graft
survival. All tests were considered statistically significant at P < . 05
Statistical analyses were performed with SPSS software (SPSS: An IBM Company,
version 13.0, IBM Corporation, Armonk, New York, USA).
Effect of rapamycin treatment on CD4+CD25+Foxp3+Tregs
Pretreatment of rapamycin significantly increased the level of CD4+CD25+Foxp3+
Tregs in peripheral blood and draining lymph nodes before allogenic penetrating
keratoplasty was performed, just as Figure 1 shows. Moreover, even at 14 days
after surgery, the level of CD4+CD25+Foxp3+Tregs in peripheral blood and
draining lymph nodes remained significantly higher in the rapamycin-treated
The score of opacity and neovascularization
Figure 2 reveals the scores of graft opacity and neovascularization, indicating
that scores in the rapamycin group were significantly lower than those of the
control group, except 3 days after surgery. Further correlation analysis
demonstrated that the scores of graft opacity and neovascularization had a
significant negative correlation with postoperative level of
CD4+CD25+Foxp3+Tregs in the peripheral blood and draining lymph nodes (opacity:
ρ=-0.762 and -0.662, neovascularization: ρ=-0.720 and -0.641; P < . 05).
CD4+CD25+Foxp3+Treg in the graft
In the rapamycin-treated group, more CD4+CD25+
T cells were found to infiltrate in the corneal grafts and conjunctiva (Figures
3A and B). Moreover, the expression level of Foxp3 gene was significantly
elevated in grafts from recipient mice treated with rapamycin, compared with
controls (2-ΔCT value:
0.072 ± 0.010 vs 0.045 ± 0.016; P < . 05).
TGF-β1 and IL-10 level in serum and aqueous humor
Compared with controls, rapamycin treatment caused significant increase of
TGF-β1 in aqueous humor (Figure 4). However, the treatment did not
influence the concentration of IL-10.
Although Tregs have strong immunosuppressive potency, they are present in low
numbers in a normal host and have an anergic phenotype, because of which it is
difficult to harness their tolerogenic potential to treat autoimmunity and
transplant rejection. So, a safe and easy method to expand Treg cells before
allogenic organ transplant is not only crucial to protect the allograft and
achieve graft acceptance, but also beneficial in reducing the dosage and adverse
effects of postoperative antirejection drugs.
The current study found that in vivo administration of rapamycin for 14 days
before allotransplant expanded CD4+CD25+Foxp3+Treg population in the peripheral
blood and draining lymph nodes, which agrees with previous
reports.15, 19 Rapamycin has been shown to allow expansion of functional
CD4+CD25+Foxp3+Treg, in vivo and in vitro.12-14 The molecular mechanism of immunosuppression mediated by rapamycin was that it bound to FK506 binding
protein 12, inhibited mammalian target of rapamycin (mTOR), and in turn,
hindered formation of the mTOR complex (mTORC).20-21 Inhibition of mTOR could
drive naïve CD4+ T cells to differentiate into Foxp3+ Tregs, with the
participation of histone H3K4me2 and
3-methylation near the Foxp3 transcriptional start
site.22-23 Moreover, Foxp3 expression induced pim2 expression in Tregs, which
allowed for a selective growth advantage of Treg in the presence of rapamycin.24
It is noteworthy that the elevated expression of CD4+CD25+Foxp3+Treg induced by
preoperative treatment of rapamycin sustained at least 2 weeks in peripheral
blood, draining lymph nodes, and corneal tissue even after the withdrawal of
rapamycin, as shown in the present study. It has been reported that in vivo
rapamycin administration contributed to selective activation and expansion of
CD4+CD25+ Foxp3+Treg, not only in peripheral blood, but also, in secondary
lymphoid organs and grafts, both of which merit graft survival.15, 25-26
Therefore, it is reasonable to deduce that the increased numbers of
CD4+CD25+Foxp3+Treg found in draining lymph nodes and corneal grafts play a
pivotal role in inhibiting graft rejection after allogenic keratoplasty.
Moreover, previous research has observed that the number of Tregs increased
shortly after rapamycin therapy was stopped, and then decreased gradually.27
This might be a possible explanation for the finding that the grafts in rapamycin-pretreated group presented little evidence of rejection, even when
no immunosuppressive drugs were used postoperatively.
The current study shows the concentration of
TGF-β1 in aqueous humor significantly increases in recipient mice
pretreated with rapamycin. It has been demonstrated that Treg cells use multiple
means to restrain inflammation including secretion of immunosuppressive
cytokines such as TGF-β1. Various studies have reported that after solid
organ transplant, elevated content of TGF-β1 was found among patients with
grafts accepted or without acute rejection episodes.28-30 On one hand,
TGF-β1 has been shown to be a stabilizer of Foxp3 expression, maintaining
the effector function of CD4+Foxp3+ Treg cells, and ultimately sustaining Treg
peripheral homeostasis. On the other hand, TGF-β1 is involved in Treg
suppressive activity, especially during the induction of allograft tolerance.31
A significant positive correlation between active suppression and TGF-β1 in
peripheral blood has been identified in renal allograft recipients.32 Our study
unveiled a similar finding that the level of TGF-β1 in aqueous humor was
significantly higher in ones with unrejected grafts. Considering the fact that
the cytokines and cells in aqueous humor, rather than those in serum, play a
predominant role in mediating immunologic reaction to the corneal graft and
determining its ultimate outcome, our findings confirm the immunomodulatory
effect of TGF-β1 produced by Treg- favored allograft acceptance.
Unexpectedly, we found levels of IL-10 in serum and aqueous humor were similar
between rapamycin-pretreated recipient mice and controls. It usually has been
accepted that IL-10 produced by Tregs plays a role in immunoregulation and
immunosuppression.33 However, the effect of IL-10 remains controversial. Pyzik
and associates and Brandenburg and associates both have demonstrated that an
elevated number of Tregs is accompanied by increased IL-10 levels in vivo, and
IL-10 neutralization abrogates the suppressive effect, in vivo and in vitro.34,
35 Moreover, IL-10 has been shown to potentiate TGF-β1 effects.36 On the
contrary, Strauss and associates reported that neither fresh CD4+CD25+ T cells
nor R0 and R1 T cells after in vitro expansion expressed IL-10 as measured by
flow cytometry.37 Pillai and associates also reported that IL-10/IL-35
double-deficient Tregs were fully functional in vitro and in vivo.38 Combining
these findings together, we suppose that Tregs induced by rapamycin pretreatment
probably exerted immunosuppressive effects through cross-regulatory pathways
other than IL-10.
The major shortcoming of this study was the relatively short follow-up after
keratoplasty because it is a pilot study. Graft outcomes after 2 weeks or even
longer remained unclear. Furthermore, how long could the population of Treg
cells sustain a level sufficient enough to inhibit rejection, which was
activated by pretreatment of rapamycin for 2 weeks, until it was insufficient to
maintain the tolerance of grafts? Is repeated therapy required to maintain the
graft transparency, and how about the injection frequencies? These issues should
be addressed by further investigations.
It also should be considered that although treatment of rapamycin after
high-risk keratoplasty has been used in a small number of patients and its
efficacy has been proved, the adverse effects remain undetermined thoroughly.39
Likewise, the dosage, administration route, and safety of rapamycin pretreatment
should be clarified before the therapeutic protocol is applied in human beings
to prevent immunologic rejection after penetrating keratoplasty.
In summary, pretreatment of rapamycin for 14 days before an allogenic corneal
transplant enhances the percentage of CD4+CD25+Foxp3+Treg cells in peripheral
blood, draining lymph nodes, and
grafts, thereby inhibiting graft rejection. Our
findings suggest that the elevated level of CD4+CD25+Foxp3+Treg cells before
allotransplant produce a beneficial effect on the induction of immunologic
tolerance and reduce the dosage and adverse effects of anti-rejection drugs
after transplantation. This protocol provides a new direction for the treatment
of immunologic rejection.
- Liang YB, Friedman DS, Wong TY, et al. Prevalence and causes of low vision
and blindness in a rural chinese adult population: the Handan Eye Study.
- Hong JX, Xu JJ, Sheng MJ, Liu Y, Zhu L. Pediatric penetrating keratoplasty in
Shanghai: a retrospective multiple centre study from 2003 to 2007. Chin Med J
- Patel SV, Diehl NN, Hodge DO, Bourne WM. Donor risk factors for graft failure
in a 20-year study of penetrating keratoplasty. Arch Ophthalmol.
- Ozbek Z, Cohen EJ, Komatsu FT, Hammersmith KM, Laibson PR, Rapuano CJ. Graft
rejection risk and incidence after bilateral penetrating keratoplasty. Eye
Contact Lens. 2008;34(3):174-178.
- Javeed A, Zhao Y. The effects of immunosuppression on regulatory
CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation.
Mol Diagn Ther. 2008;12(3):171-181.
- Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance
maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).
Breakdown of a single mechanism of self-tolerance causes various autoimmune
diseases. J Immunol. 1995;155(3):1151-1164.
- Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type
CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease
after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
- Shevach EM. Regulatory T cells in autoimmmunity*. Annu Rev Immunol.
- Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained
by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity,
tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182(1):18-32.
- Korczak-Kowalska G, Wierzbicki P, Bocian K, et al. The influence of
immunosuppressive therapy on the development of CD4+CD25+ T cells after renal
transplantation. Transplant Proc. 2007;39(9):2721-2723.
- Thompson P, Xu D, Brunette I, Chen H. Combined effect of rapamycin and
cyclosporine in the prevention of rat corneal allograft rejection. Transplant
- Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T,
Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+
regulatory T cells of both healthy subjects and type 1 diabetic patients. J
- Bocian K, Borysowski J, Wierzbicki P, et al. Rapamycin, unlike cyclosporine
A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs. Nephrol
Dial Transplant. 2010;25(3):710-717.
- Lim DG, Koo SK, Park YH, et al. Impact of immunosuppressants on the
therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in
allotransplantation. Transplantation. 2010;89(8):928-936.
- Hendrikx TK, Velthuis JH, Klepper M, et al. Monotherapy rapamycin allows an
increase of CD4+ CD25bright+ FoxP3+ T cells in renal recipients. Transpl Int.
- Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands
CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105(12):4743-4748.
- Joo CK, Pepose JS, Stuart PM. T-cell mediated responses in a murine model of
orthotopic corneal transplantation. Invest Ophthalmol Vis Sci.
- Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice--evidence
that the immunogenetic rules of rejection do not apply. Transplantation.
- Qu Y, Zhang B, Zhao L, et al. The effect of immunosuppressive drug rapamycin
on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol.
- Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell
differentiation, function, and metabolism. Immunity. 2010;33(3):301-311.
- Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell.
- Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially
regulates effector and regulatory T cell lineage commitment. Immunity.
- Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls
Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A.
- Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge:
Foxp3-mediated induction of pim 2 allows human T regulatory cells to
preferentially expand in rapamycin. J Immunol. 2008;180(9):5794-5798.
- Li S, Kuang A, Huang R. Can proliferation signal inhibitor-induced Tregs
really reflect transplantation tolerance in clinical solid organ
transplantation? Int Rev Immunol. 2009;28(5):367-375.
- Salama AD, Najafian N, Clarkson MR, Harmon WE, Sayegh MH. Regulatory CD25+ T
cells in human kidney transplant recipients. J Am Soc Nephrol.
- Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects
of cyclosporine and rapamycin in de novo generation of alloantigen-specific
regulatory T cells. Am J Transplant. 2007;7(7):1722-1732.
- Amirzargar A, Lessanpezeshki M, Fathi A, et al. TH1/TH2 cytokine analysis in
Iranian renal transplant recipients. Transplant Proc. 2005;37(7):2985-2987.
- Alberú J, Richaud-Patin Y, Vázquez-Lavista LG, et al. In vivo IL-10 and
TGF-beta production by PBMC from long-term kidney transplant recipients with
excellent graft function: a possible feedback mechanism participating in
immunological stability. Clin Transplant. 2004;18(2):174-178.
- Velásquez-Lopera MM, Eaton VL, Lerret NM, et al. Induction of
transplantation tolerance by allogeneic donor-derived CD4(+)CD25(+)Foxp3(+)
regulatory T cells. Transpl Immunol. 2008;19(2):127-135.
- Mohammadnia M, Solgi G, Ranjbar M, et al. Serum levels of interleukin
(IL)-10, IL-17, transforming growth factor (TGF)-β1, and interferon-γ
cytokines and expression levels of IL-10 and TGF-β1 genes in renal
allograft recipients after donor bone marrow cell infusion. Transplant Proc.
- Spadafora-Ferreira M, Caldas C, Faé KC, et al. CD4+CD25+Foxp3+ indirect
alloreactive T cells from renal transplant patients suppress both the direct and
indirect pathways of allorecognition. Scand J Immunol. 2007;66(2-3):352-361.
- Okamoto A, Fujio K, Okamura T, Yamamoto K. Regulatory T-cell-associated
cytokines in systemic lupus erythematosus. J Biomed Biotechnol.
- Pyzik M, Piccirillo CA. TGF-beta1 modulates Foxp3 expression and regulatory
activity in distinct CD4+ T cell subsets. J Leukoc Biol. 2007;82(2):335-346.
- Brandenburg S, Takahashi T, de la Rosa M, et al. IL-2 induces in vivo
suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol.
- Cottrez F, Groux H. Regulation of TGF-beta response during T cell activation
is modulated by IL-10. J Immunol. 2001;167(2):773-778.
- Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A.
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T
cells cultured with rapamycin. J Immunol. 2007;178(1):320-329.
- Pillai MR, Collison LW, Wang X, et al. The plasticity of regulatory T cell
function. J Immunol. 2011;187(10):4987-4997.
- Birnbaum F, Reis A, Böhringer D, et al. An open prospective pilot study on
the use of rapamycin after penetrating high-risk keratoplasty. Transplantation.
Volume : 11
Issue : 1
Pages : 56-62
From the Department of Ophthalmology, Eye and ENT Hospital of Fudan University,
Acknowledgements: Supported by National Natural Science Grant (30901633) and
Phosphorus Program from Shanghai Science and Technology Committee (11QA1401000).
The authors report no conflicts of interest.
Corresponding author: Qihua Le, Department of Ophthalmology, Eye & ENT Hospital
of Fudan University, Shanghai 200031, China
Phone: +86 21 6437 7134 ext: 672
Fax: +86 21 6437 7151
Table 1. Clinical Scoring Criteria for Orthotopic Corneal Grafts
Figure 1. The Percentage of CD4+CD25+Foxp3+Treg in Blood, Spleen, and Draining
Figure 2. Pretreatment of Rapamycin Could Reduce the Score of Graft Opacity and
Neovascularization After Subsequent Allogenic Penetrating Keratoplasty, Except 3
Figure 3. Immunostaining of CD4+CD25+ T Cells in Corneal Grafts and Conjunctiva
Figure 4. Comparison of TGF-β1 and IL-10 Levels